Trial Profile

A Phase 1/2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 May 2025 Planned End Date changed from 1 Mar 2025 to 1 May 2026.
02 May 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2026.
13 Jan 2025 According to an Ashvattha Therapeutics media release, the company has announced additional financing as an extension of its Series B of up to $50 million led by Tribe Capital with existing investors led by Natural Capital. The funding will enable company to complete this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com